Skip to main content

Table 2 Hematological toxicity criteria for irinotecan dose adjustment

From: Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and reduce target lesions in patients with locally recurrent or metastatic Her-2-negative breast cancer? Study protocol for a randomized controlled trial

Minimal valueDose in the next cycle
Neutrophil count (×  109/L)Platelet count (×  109/L)
≥ 0.5… and ≥ 50No change
<  0.5 or ≥ 0.5 accompanied by fever and lack of granulocytes… or < 50Irinotecan dose decreased by 20%